Novel Wrist Sensor System to Promote Hemiparetic Arm Use in Home Daily Life of Chronic Stroke Survivors

Stroke Clinical Trial

Official title:

A Novel Wrist Wearable Sensor System to Promote Hemiparetic Upper Extremity Use in Home Daily Life of Chronic Stroke Survivors

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05626894
• Other study ID #: 2022P002943
• Secondary ID: R44HD084035
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: September 1, 2023
• Est. completion date: September 30, 2025

Study information

• Verified date: May 2023
• Source: Spaulding Rehabilitation Hospital
• Contact: Paolo Bonato, PhD
• Phone: 617-952-6319
• Email: pbonato[@]partners.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The proposed study is a two-arm randomized clinical trial designed to assess the effects of the StrokeWear system on clinical outcomes over a period of 6-months in chronic stroke survivors. The Intervention group will use StrokeWear system in combination to a motor and behavioral home intervention whereas the Control group will follow usual care which consists of a home-exercise plan (HEP).

Description:

The proposed study is a two-arm randomized clinical trial designed to assess the effects of the StrokeWear system on clinical outcomes over a period of 6-months in chronic stroke survivors. The Intervention group will use StrokeWear system in combination to a motor and behavioral home intervention whereas the Control group will follow usual care which consists of a home-exercise plan (HEP).

Study participants will be asked to take part in 4 evaluation study visits: one screening and enrollment visit, and three evaluation visits (at baseline, at 3 months and at 6 months - at the intervention completion). Subject upper-extremity motor function will be assessed across domains of the International Classification of Functioning, Disability and Health (ICF) model. Groups will be stratified by baseline motor impairment and stroke chronicity.

Subjects randomized to the intervention group will take part of weekly coaching sessions during the first month, bi-weekly sessions during the months 2 and 3, and monthly sessions during months 4-6. These sessions will be held in-person or remotely, based on the study participant preference.

Subjects randomized to the control group will take part of monthly visits, held in-person or remotely (based on study participant preference), to re-evaluate the home-exercise plan and prescribe an update list of exercises for the following month.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 32
• Est. completion date: September 30, 2025
• Est. primary completion date: June 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Male or female, 18-85 years of age at the time of enrollment;

• Anterior circulation ischemic stroke at least 6 months and up to 5 years prior to study enrollment;

• Unilateral upper extremity hemiparesis as characterized by initial scores on upper limb subtest of the Fugl-Meyer Assessment (FMA-UE) between 20 and 45;

• Intact cognitive function to understand the study procedures and goal setting (MMSE score above 23 and able to follow 3 step command);

• Being familiar and comfortable with the use of a tablet or smartphone.

Exclusion Criteria:

• Severe spasticity (defined as a Modified Ashworth scale score of 3 or more) that would prevent safe performance of UE tasks;

• Visual impairments as assessed by the NIH Stroke Scale Visual Field subscale (only subjects with no visual loss will participate in the study); or hemispatial neglect that would impair the subject ability to see feedback on the app screen (as assessed with the star cancellation test);

• Individuals with open wounds or recent fracture (less than 3 months) in the UE, fragile skin or active infection as evaluated by the study therapist;

• Individuals currently enrolled in a UE rehabilitation program (i.e., OT, research study)

• Upper-extremity orthopedic injuries or severe pain resulting in movement limitations;

• Diagnosis of other neurological disease (i.e., Parkinson's disease, multiple sclerosis, ...);

• Severe proprioceptive deficits that impair the ability to process the vibration feedback, as assessed by physical examination during screening as assessed by the study therapist;

• Not understanding spoken or written English;

• Recent (less than 3 months) Botox injection in the UE or plan to undergo injections during the study timeline;

• Contralateral motor deficits as assessed by clinical examination;

• Brainstem and cerebellar stroke.

Related Conditions & MeSH terms

• Hemiparesis;Poststroke/CVA
• Paresis
• Stroke
• Stroke Sequelae

Intervention

Combination Product:
• StrokeWear Motor and Behavioral Intervention
The intervention will consist of 1) the use of StrokeWear for goal directed movements (GDM) feedback and goal setting, 2) use of daily activity action planning (DAAP) to foster planned hemiparetic UE use during daily activities in the home and community, and 3) patient empowerment. Patient empowerment in this study will occur over 6-months as patients gain the ability to use the StrokeWear technology independently and develop skills to manage their GDM and DAAP.

Other:
• Usual Care
The intervention will consist in a sham version of the StrokeWear system and usual clinical care under the direction of a clinician. The sham version of the StrokeWear system will include sensing and recording technology to detect GDMs. However, study participants will not receive feedback from the system regarding the GDM counts.

Locations

Country	Name	City	State
United States	Spaulding Rehabilitation Hospital Boston	Boston	Massachusetts

Sponsors (4)

Lead Sponsor	Collaborator
Spaulding Rehabilitation Hospital	BioSensics, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), MGH Institute of Health Professions

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change in Canadian Occupational Performance Measure (COPM)	Semi-structured interview to assess outcomes in the areas of self-care, productivity and leisure. Score from 0 (worst) to 10 (best).	Change from baseline Canadian Occupational Performance Measure (COPM) score at 6 months
Other	Number of times the activity goals are reached	Number of times the activity goals set are reached over the study duration	At 6 months
Primary	Change in Motor Activity Log-Amount of Use	Self-reported measure of upper-extremity performance. Score from 0 (worst) to 5 (best)	Change from baseline Motor Activity Log-Amount of Use score at 6 months
Primary	Change in Fugl-Meyer Upper-Extremity	Observed measure of upper-extremity motor impairment following a stroke. Score from 0 (worst) to 66 (best)	Change from baseline Fugl-Meyer Upper-Extremity score at 6 months
Primary	Change in Upper-Extremity Activity Counts	Activity of the hemiparetic upper-extremity in the home setting as measured with wrist-worn accelerometers	Change from baseline Upper-Extremity Activity Counts score at 6 months
Secondary	Change in Motor Activity Log-Quality of Use	Self-reported measure of upper-extremity quality of use. Score from 0 (worst) to 5 (best)	Change from baseline Motor Activity Log-Quality of Use score at 6 months
Secondary	Change in Wolf-Motor Function Test - Time subscale	Observed (timed) measure of upper-extremity function. Time from 0 to 120 seconds (maximum time allowed to attempt to perform a motor task)	Change from baseline Wolf-Motor Function Test - Time subscale score at 6 months
Secondary	Change in Wolf-Motor Function Test - Functional ability subscale	Measure of upper-extremity quality of movement based on visual observation. Score from 0 (worst) to 5 (best)	Change from baseline Wolf-Motor Function Test - Functional ability subscale score at 6 months
Secondary	Change in Stroke Impact Scale (SIS)	Self-reported measure of quality of life after a stroke. Score from 0 (best) to 42 (worst)	Change from baseline Stroke Impact Scale (SIS) score at 6 months
Secondary	Change in Stroke Self-Efficacy Questionnaire (SSEQ) - Activity subscale	Self-reported measure of upper-extremity efficacy in activities of daily living. Score from 0 (worst) to 10 (best).	Change from baseline Stroke Self-Efficacy Questionnaire (SSEQ) - Activity subscale score at 6 months
Secondary	Change in Stroke Self-Efficacy Questionnaire (SSEQ) - Self-management subscale	Self-reported measure of upper-extremity efficacy in activities of daily living. Score from 0 (worst) to 10 (best).	Change from baseline Self-Efficacy Questionnaire (SSEQ) - Self-management subscale score at 6 months